BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 11931347)

  • 1. (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
    Moody TW; Jensen RT; Fridkin M; Gozes I
    J Mol Neurosci; 2002; 18(1-2):29-35. PubMed ID: 11931347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
    Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors in chick cerebral cortex.
    Zawilska JB; Niewiadomski P; Nowak JZ
    J Mol Neurosci; 2003 Apr; 20(2):153-62. PubMed ID: 12794309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
    Van Rampelbergh J; Gourlet P; De Neef P; Robberecht P; Waelbroeck M
    Mol Pharmacol; 1996 Dec; 50(6):1596-604. PubMed ID: 8967982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.
    Jamen F; Puech R; Bockaert J; Brabet P; Bertrand G
    Endocrinology; 2002 Apr; 143(4):1253-9. PubMed ID: 11897681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
    Zawilska JB; Niewiadomski P; Nowak JZ
    Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pituitary adenylate cyclase-activating peptide stimulates acute progesterone production in rat granulosa/Lutein cells via two receptor subtypes.
    Gräs S; Hedetoft C; Pedersen SH; Fahrenkrug J
    Biol Reprod; 2000 Jul; 63(1):206-12. PubMed ID: 10859261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP.
    Leceta J; Gomariz RP; Martinez C; Abad C; Ganea D; Delgado M
    Ann N Y Acad Sci; 2000; 921():92-102. PubMed ID: 11193883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding.
    Zawilska JB; Dejda A; Niewiadomski P; Gozes I; Nowak JZ
    J Mol Neurosci; 2005; 25(3):215-24. PubMed ID: 15800375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells.
    Sharma A; Walters J; Gozes Y; Fridkin M; Brenneman D; Gozes I; Moody TW
    J Mol Neurosci; 2001 Dec; 17(3):331-9. PubMed ID: 11859929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain.
    Joo KM; Chung YH; Kim MK; Nam RH; Lee BL; Lee KH; Cha CI
    J Comp Neurol; 2004 Aug; 476(4):388-413. PubMed ID: 15282712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.
    Mazzocchi G; Malendowicz LK; Neri G; Andreis PG; Ziolkowska A; Gottardo L; Nowak KW; Nussdorfer GG
    Int J Mol Med; 2002 Mar; 9(3):233-43. PubMed ID: 11836629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.
    Schulz S; Röcken C; Mawrin C; Weise W; Höllt V; Schulz S
    Clin Cancer Res; 2004 Dec; 10(24):8235-42. PubMed ID: 15623599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maxadilan specifically interacts with PAC1 receptor, which is a dominant form of PACAP/VIP family receptors in cultured rat cortical neurons.
    Tatsuno I; Uchida D; Tanaka T; Saeki N; Hirai A; Saito Y; Moro O; Tajima M
    Brain Res; 2001 Jan; 889(1-2):138-48. PubMed ID: 11166697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and functional properties of the pituitary adenylate cyclase activating peptide (PAC1) receptor in human benign hyperplastic prostate.
    Solano RM; Carmena MJ; Busto R; Sánchez-Chapado M; Guijarro LG; Prieto JC
    Cell Signal; 1999 Nov; 11(11):813-9. PubMed ID: 10617284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
    Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
    Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines.
    Zia H; Leyton J; Casibang M; Hau V; Brenneman D; Fridkin M; Gozes I; Moody TW
    Life Sci; 2000; 66(5):379-87. PubMed ID: 10670826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide inhibit dendritic growth in cultured sympathetic neurons.
    Drahushuk K; Connell TD; Higgins D
    J Neurosci; 2002 Aug; 22(15):6560-9. PubMed ID: 12151535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors.
    Juarranz MG; Bolaños O; Gutiérrez-Cañas I; Lerner EA; Robberecht P; Carmena MJ; Prieto JC; Rodríguez-Henche N
    Cell Signal; 2001 Dec; 13(12):887-94. PubMed ID: 11728828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.